Uscom

2017 Update Continued Growth

Rob Phillips
PhD(med), MPhil(med), FASE, DMU(cardiol)
Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland
Uscom Executive Chairman/CEO

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA.
The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

Uscom

Mission

"Uscom is a leading innovator in cardiovascular and pulmonary medical devices, developing new technologies to address the challenges of global disease and health care.

Uscom is driven by a commercial ambition to become a leader in global health business."

Uscom

Invested in the future

Growth by acquisition

Acquired 2013

Acquired 2015

Incremental shareholder value
Two companies
    Pulsecor – 2013
    Thor – 2015
Two product suites
    BP+
    SpiroSonic
Two global revenue streams starting 2017
IP and product reservoir

World leading technologies
Stand alone companies
Growth strategy
Efficiencies of scale
Investment
Operational integration
Product development
Regulatory
Revenue - 2017

Technology

"Digital medical device innovations to improve the physician experience and patient outcomes."



Digital Doppler Ultrasound



Suprasystolic Oscillometry

Digital Transit time Ultrasound

New generation digital cardiovascular pulmonary devices.

Applications

Sector leading technologies

Fluid, Sepsis & Heart Failure

- US $1.3bn market *
- CAGR of 7.6% *
- CE, FDA, TGA, CFDA

Hypertension & Vascular Health

- US $1.7bn market *
- CAGR of 11.5% *
- CE, FDA, TGA

COPD & Asthma

- US $400m market *
- CAGR of 6.5% *
- CE, TGA, FDA

USCOM 1A

Cardiac Output Monitoring



BP+

Blood Pressure Monitoring

SpiroSonic

Pulmonary Monitoring

Uscom – Devices the experts use

* Source: MedTech Insight; Transparency Market Research

Changing outcomes

36 new publications in 2016



Changing the lives of children with septic shock in India

Ranjit S, Natraj R, Kandath SK, Kissoon N, Ramakrishnan B, Marik P. Early nor-epinephrine decreased fluid and ventilatory requirements in paediatric septic shock. Indian J Crit Care Med 2016;20:561-9.

Meeting clinical needs



*Uscom devices address conditions responsible for **80%** of leading causes of death worldwide (WHO criteria).*

Heart failure, sepsis, hypertension, asthma, COPD.

Uscom

http://www.who.int/mediacentre/factsheets/fs310/en/ - accessed 4th Aug 2016

2016 Results





*Total revenue **+44%** to $2.94m*

*Receipts from Customers **+94%** to $2.56m*

Uscom

A year of growth and investment

2016 Results

Quarterly Total Revenue



Revenue 3yr CAGR 43%

Quarterly Cash Receipts



Cash Receipts 3 yr CAGR 60%

Uscom

A year of growth and investment

2016 Results



+440% **+30%** **+116%** **+95%**

A year of growth and investment

* Estimate

2016 Results

Growth:

Record revenue, sales, cash, share price, cap value (+44 to +116%)

And investment:

Acquired and consolidated Thor laboratories into Uscom

One off investments:

- acquisition and integration (≈$1m)
- BP+ and SpiroSonic product series prepared for revenue in 2017 (≈$0.5m)
- global corporate model established

Transformational $65m 5yr China agreement

Approaching profitability with two new device series for sale in 2017

Uscom

A year of growth and investment

2016

“Growth as planned!”

Uscom - 2016

" Investors can review Uscom's progress in 2016 with satisfaction and look forward to the rewards of 2017 and beyond.

Uscom has invested in the future, and investors will share in the profits of this investment as we continue to meet our milestones."

Uscom

Great Brands

Uscom

SpiroSonic
Uscom

BP

Unrecognised value

Great Products

Real devices, real value, real revenue

Uscom

New Markets

Telemonitoring asthma and COPD

Digital ultrasonic spirometers
Wireless connectivity
Proprietary apps and software
Diagnostic and therapeutic monitoring
Leading pulmonary monitors in eHealth
450 sold into the US (2016)
Growing global market

Uscom digital spirometers

Uscom Phone App





SpiroReporter software

Bringing patients and clinicians together – The digital eHealth future

Uscom

Global distribution

Delivering multiple products into multiple jurisdictions

1. Uscom Sydney
2. Uscom London
3. Uscom Budapest
4. Uscom LA
5. Uscom Shanghai



Key Markets

Asia
Europe
Nth America

Focus FY 2017

Asia – Establish CIIC
US – BP+ and SpiroSonic release
Global tSpiro partnerships

Uscom

Distribution

Medica – Taking Uscom products to the world

Three leading product lines

Global distribution

130,000 Delegates

5,000 Exhibitors

New distributors in advance of regulatory approvals



MEDICA®

Uscom

Distributors are feet on the ground - revenue

**Aniticipated*

China partnerships

Uscom – CIIC China state owned partnership

CIIC to import $65m of Uscom devices and support regulatory over 5 yrs

Health spend from 6-12% of GDP

1.35b population in 31 provinces

Revenue targets in China $20m

Uscom positioning to grow with China - $20m pa revenue target

Uscom

Global manufacturing

Uscom owns approved manufacturing facilities in Sydney and Hungary

Currently

- USCOM 1A and BP+ in Sydney
- SpiroSonic in Hungary

Future

- SpiroSonic and BP+ in Hungary





Worldwide regulatory

The path to global markets

Uscom has established in house skills in regulatory approval of medical devices

- Europe - CE
- China – CFDA
- USA - FDA 510k
- Multiple small jurisdictions (TGA etc.)

CE is also used for other countries as a basis for registration

Uscom

Regulatory

Jurisdictions

	Products	2016			2017		
		CFDA	CE	FDA	CFDA	CE	FDA
1	USCOM 1A	✓	✓	✓	✓	✓	✓
2	Uscom BP+	★	★	★	★	★	★
3	Uscom BP+Reporter	★	★	★	★	★	★
4	SpiroSonic Flo	★	★	★	★	✓	★
5	Smart	★	★	★	★	✓	★
6	Mobile	★	★	★	★	✓	★
7	Pro	★	★	★	★	✓	★
8	SpiroReporter	★	★	★	★	✓	★
9	tSpiro	★	★	★	★	✓	★
10	SpiroApp	★	★	★	★	✓	★

New Products

★ In preparation/submitted ★ Expected ✓ Achieved

Uscom

Three global brands

Uscom

SpiroSonic
Uscom

BP

Science – R&D - Manufacture – Regulatory – Market - Revenue

Three revenue streams

Uscom

2017 milestones

Mission -	Capitalise on investments - profitability with growth
	HY 2017 results in February
More products -	Global launch BP+ (+2 products)
	Global launch SpiroSonic (+7 products)
More Revenue -	Continue USCOM sales growth
	Global pricing
	More and better distribution
	Cross distribute USCOM/BP+/SpiroSonic
	Reimbursement drive
Global operations –	Grow US, UK and European operations
	Grow China
Market value -	Grow company fundamentals and shareholder value

Uscom has a history of meeting our milestones

Uscom

News!

European Research Grant to Develop **Lung Cancer Diagnostic**

NATIONAL RESEARCH, DEVELOPMENT AND INNOVATION OFFICE

Uscom

"To develop a simple breath test device for early diagnosis of lung cancer and a wide range of viral, microbial, neoplastic (cancer) and genetic diseases."

Based on world leading digital, multi-path ultrasonic spirometer technology for measurement and analysis of respiratory flow.

Uscom

Uscom - global reputation for excellence in science

News!

Closing 2016 with **Record Manufacturing**

December month - **record manufactured units**

December quarter – record manufactured units (**42% of full FY 2016**)

December half – **up 28%** on prior half

1000th USCOM 1A manufactured

Uscom has a history of meeting our milestones

Uscom

2017

"Uscom has acquired global assets to ensure reliable revenue growth and long term profitability.

Our strategy is to efficiently deliver the devices we have developed into global markets.

Establish a culture of profitable performance and future shareholder dividends."

Uscom

2017

"Continued growth as planned"

Uscom

2017 Update Continued Growth

Thanks

Rob Phillips
PhD(med), MPhil(med), FASE, DMU(cardiol)
Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland
Uscom Executive Chairman/CEO